{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-040396","form_type":"8-K","ticker":"TIL","cik":"0001789769","company_name":"Instil Bio, Inc.","filed_at":"2024-09-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.534193+00:00","generated_at":"2026-05-31T04:39:57.906916+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Instil Bio and ImmuneOnco outline global registrational strategy for SYN-2510 in NSCLC and TNBC","bullets":["Global registrational strategy for SYN-2510/IMM2510 in front-line NSCLC and TNBC announced.","Phase 1b/2 chemo combo in front-line NSCLC expected to start late 2024 in China; US IND submission for SYN-2510 targeted late 2024 for Phase 2 monotherapy in second-line NSCLC.","Phase 1b/2 chemo combo in front-line TNBC expected to start early 2025 in China; potential global Phase 3 trials after proof-of-concept.","US Phase 2 monotherapy trial in second-line NSCLC expected to support efficient enrollment of global Phase 3 studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-040396","json":"https://secwatch.observer/filing/0001628280-24-040396.json","markdown":"https://secwatch.observer/filing/0001628280-24-040396.md","text":"https://secwatch.observer/filing/0001628280-24-040396.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789769/000162828024040396/0001628280-24-040396-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789769/000162828024040396/til-20240916.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T04:39:57.906916+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}